eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
1/2019
vol. 36
 
Share:
Share:
more
 
 
abstract:
Original paper

How fast does wasp venom immunotherapy affect a regulatory T cell subpopulation (CD4+ CD25+ Foxp3+) and the synthesis of interleukins 10, 21 and transforming growth factor β1?

Aleksander Zakrzewski, Jerzy Kruszewski, Andrzej Chciałowski, Krzysztof Kłos, Agnieszka Rzeszotarska, Jolanta Korsak, Ewa M. Nowosielska, Aneta Cheda, Jolanta Wrembel-Wargocka, Marek K. Janiak

Adv Dermatol Allergol 2019; XXXVI (1): 82-85
Online publish date: 2019/02/22
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
The literature describes the influence of venom immunotherapy (VIT) on the subpopulation of T regulatory cells (CD4+ CD25+ Foxp3+) and the synthesis of IL-10, TGF-1 as well as many other cytokines at various times after immunotherapy.

Aim
To assess changes in the percentage of cells of CD4+ and CD25+ in peripheral blood and serum concentrations of IL-10, IL-21 and TGF-1 in the early stages of VIT.

Material and methods
The study included 18 patients who were allergic to wasp venom and who in the past underwent systemic anaphylactic reaction after stinging, meeting the criteria to qualify for VIT. The immunoenzymatic method (ELISA) was used to assess concentrations of cytokines IL-10, IL-21 and TGF-1 and the surface antigens CD4 and CD25 on the cells. The concentrations were determined by flow cytometry method at baseline (before VIT) and after 2.5 and 24 h from the VIT starting point.

Results
The mean values of the activity of T lymphocytes CD4+ CD25+ FoxP3+ and concentrations of the cytokines IL-10, IL-21 and TGF-1 are shown in table.

Conclusions
A 24-hour activation assessment of serum concentrations of cytokines IL-10, IL-21 and TGF-1 during the first day of the Hymenoptera venom immunotherapy by ultra-rush protocol does not show the significant dynamics of change of the examined parameters.

keywords:

cytokines, regulatory cells, Hymenoptera venom immunotherapy

references:
Fujita H, Soyka MB, Akdis M, et al. Mechanisms of allergen-specific immunotherapy. Clin Transl Allergy 2012; 2: 2.
Jutel M. Pathophysiologic basis for immunotherapy. Postep Dermatol Alergol 2003; 20: 125-9.
Kempiński K, Niedoszytko M. The effectiveness of immunotherapy in allergy to the Hymenoptera venom. Allergy Immun Asthma 2011; 16: 123-31.
Krishna MT, Ewan PW, Diwakar L, et al. Diagnosis and management of hymenoptera venom allergy: British Society of Allergy and Clinical Immunology (BSACI) guidelines. Clin Exp Allergy 2011; 41: 1201-20.
Krishna MT, Huissoon AP. Clinical immunology review series: an approach to desensitization. Clin Exp Immunol 2010; 163: 131-46.
Yacoub MR, Incorvaia C, Caminati M, et al. Immune mechanisms of allergen-specific immunotherapy. Open Immunol J 2012; 5: 47-52.
Grad A, Jung A, Stankiewicz W, et al. The answer of selected immunological parameters during subcutaneous specific immunotherapy and sublingual specific immunotherapy. Allergol Info 2009; 4: 22-9.
Moote W, Kim H. Allergen-specific immunotherapy. Asthma Clin Immunol 2011; 7 Suppl. 1: 55-61.
Ozdemir C, Kucuksezer UC, Akdis M, et al. Mechanisms of immunotherapy to wasp and bee venom. Clin Exp Allergy 2011; 41: 1226-34.
Song WJ. Mechanisms of allergen-specific immunotherapy. KAAACI Annual International Congress and East Asia Allergy Symposium, Alpensia Resort, Gangwon-do, November 13, 2012; S105-111.
Akdis CA, Adkis M. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 2011; 127: 18-27.
Cichocka-Jarosz E, Brzyski P, Lis G, et al. Diagnostics and immunotherapy in children with allergy to the Hymenoptera venom (VIT) in Poland – what does the compliance with international guidelines look like in practice? Przegl Lek 2010; 67: 1-5.
Cichocka-Jarosz E, Diwakar L, Brzyski P, et al. Congruence of the current practices in Hymenoptera venom allergy patients in Poland with EAACI guidelines. Arch Med Sci 2011; 7: 832-9.
Dowbór-Dzwonka A, Cegła B, Filanowicz M, et al. Supersensitization to the Hymenoptera venom. Hygeia Public Health 2012; 47: 157-63.
Dreschler K, Bratke K, Petermann S, et al. Impact of immunotherapy on blood dendritic cells in patients with Hymenoptera venom allergy. J Allergy Clin Immunol 2011; 127: 487-94.
Duan W, So T, Mehta AK, et al. Inducible CD4+LAP+Foxp3 regulatory T cells suppress allergic inflammation. J Immunol 2011; 187: 6499-507.
Pereira-Santos MC, Baptista AP, Melo A, et al. Expansion of circulating Foxp3+CD25brightCD4+ T cells during specific venom immunotherapy. Clin Exp Allergy 2007; 38: 291-7.
Przybilla B, Ruëff F. Insect stings. Dtsch Arztebl Int 2012; 109: 238-48.
Riccio AM, Saverino D, Pesce G, et al. Effects of different up-dosing regimens for hymenoptera venom immunotherapy on serum CTLA-4 and IL-10. PLoS One 2012; 7: e37980.
Sanz C, Isidoro-Garcia I, Davila I. Modulation of the serum cytokine expression pattern in Hymenoptera allergic patients treated with specific venom immunotherapy. Open Immunol J 2012; 5: 13-9.
Patella V, Florio G, Giuliano A, et al. Hymenoptera venom immunotherapy: tolerance and efficacy of an ultrarush protocol versus a rush and a slow conventional protocol. J Allergy 2012; 2012: 192192.
Taylor A, Verhagen J, Blaser K, et al. Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: the role of T regulatory cells. Immunology 2006; 117: 433-42.
Jutel M, Akdis M, Blaser K, et al. Are regulatory T cells the target of venom immunotherapy? Curr Opin Allergy Clin Immunol 2005; 5: 365-9.
Memessier E, Brinbaum J, Dupuy P, et al. Ultra-rush venom immunotherapy induces differentia T cell activation and regulatory patterns according to the severity of allergy. Clin Exp Allergy 2006; 36: 704-13.
Bussmann C, Xia J, Allam JP, et al. Early markers for protective mechanism during rush venom immunotherapy. Allergy 2010; 61: 1558-65.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe